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Abstract: The development of the coxib family has represented a stimulating approach in the treatment of inflammatory disorders, such 
as arthritis, and for the management of acute pains, in relation to the well-known traditional Non-Steroidal Anti-inflammatory Drugs (t-
NSAIDs). Prompted by the pursuit for new cyclooxygenase-2 (COX-2) inhibitors, endowed with fine tuned selectivity and high potency, 
in the past years we have identified novel classes of ether, ester and acid molecules characterized by the 1,5-diarylpyrrole scaffold as po-
tentially powerful anti-inflammatory molecules (12-66). All compounds proved to exert an in vitro inhibition profile as good as that 
shown by reference compounds. Compounds bearing a p-methylsulfonylphenyl substituent at C5 displayed the best issues. In particular, 
ester derivatives proved to perform the best in vitro profile in terms of selectivity and activity toward COX-2. The cell-based assay data 
showed that an increase of hindrance at the C3 side chain of compounds could translate to activity enhancement. The human whole blood 
(HWB) test let to highlight that submitted compounds displayed 5-10 fold higher selectivity for COX-2 vs COX-1 which should translate 
clinically to an acceptable gastrointestinal safety and mitigate the cardiovascular effects highlighted by highly selective COX-2 inhibi-
tors. Finally, to assess in vivo anti-inflammatory and analgesic activity three different tests (rat paw pressure, rat paw oedema and ab-
dominal constriction) were performed. Results showed good in vivo anti-inflammatory and analgesic activities. The issues gained with 
these classes of compounds represent, nowadays, a potent stimulus for a further enlargement of the NSAIDs family. In this review we de-
scribe the results obtained by our research group on this topic. 
Keywords: COX-2 inhibitors, COX-1 inhibitors, Anti-inflammatory agents, Analgesic agents, Celecoxib, Pyrrole derivatives, Coxibs, t-
NSAIDs. 
INTRODUCTION 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are efficacious 
drugs for the management of musculoskeletal symptoms. They are 
a chemically heterogenous group of compounds which shares the 
same mechanism of action, i.e. the inhibition of prostanoids [1]. 
Prostanoids [prostaglandin(PG)E2, PGF2a, thromboxane(TX)A2 and 
prostacyclin(PGI2)] are biologically active derivatives of arachi-
donic acid(AA) generated through the activity of prostaglandin H 
synthases (popularly known as COX-1 and COX-2) [2]. Although 
COX-1 and COX-2 share the same catalytic activities, cyclooxy-
genase and peroxidase [3], they are differently regulated both cata-
lytically and transcriptionally. In fact, it has been shown that 
COX-2 requires considerably lower levels of hydroperoxides to 
initiate cyclooxygenase catalysis than those required by COX-1 
[4]. Moreover, the COX-2 activity occurs at lower levels of free 
AA than COX-1 activity [5]. Another important difference be-
tween the two pathways of prostanoid biosynthesis is related to 
the regulation of the expression of COX-1 and COX-2 genes. In 
fact, while COX-1 has the structural features of an “housekeep-
ing” gene, COX-2 is an immediate early gene [6, 7a-c]. Thus, 
COX-1 is constitutively expressed in almost all tissues and it is 
responsible for those physiological functions such as gastrointesti-
nal cytoprotection, platelet aggregation and vascular smooth muscle 
tone modulation [8, 9]. On the other hand, COX-2, the second iso-
form, identified as an inducible enzyme, is highly expressed in 
response to interleukin-1? (IL-1?) and other inflammatory stimuli 
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[9]. However, this strict separation of the COX-1 and COX-2 func-
tion, as constitutive and inducible, respectively, is now considered 
naïve. In fact, in-depth knowledge of COX-isoform biology has 
shown that COX-1 can be up-regulated in some circumstances 
(such as cell differentiation) and COX-2 can be constitutively ex-
pressed in physiologic conditions, such as in central nervous sys-
tem, vasculature and kidney [10a-e]. Due to the fact that COX-1 is 
constitutively expressed in the GI system and that prostanoids gen-
erated by this pathway, play several protective actions for this sys-
tem, it was proposed “the COX-2 hypothesis” which claimed that at 
comparable COX-2 inhibiting doses, selective COX-2 inhibitors 
(coxibs) would be as effective as traditional (t) NSAIDs and cause 
less gastrointestinal adverse effects putatively due to COX-1 inhibi-
tion [6, 11]. Thus, several coxibs, structurally unrelated to tNSAIDs 
(Chart 1), were developed [ie celecoxib (6), SC588 (7) rofecoxib 
(8), valdecoxib (9), parecoxib (10) and later etoricoxib (11) and 
lumiracoxib (12)] (Chart 2) [12a, b]. 
The development of whole blood assay to assess selectivity to-
wards COX-isozymes by tNSAIDs and coxibs was an essential tool 
to cluster NSAIDs based on their pharmacodynamics, i.e. their 
inhibition towards the activity of platelet COX-1 versus that of 
COX-2 in monocytes described by COX-1/COX-2 IC50 ratios (ratio 
of the concentration which inhibits by 50% the activity of COX-1 
and COX-2 in vitro) [12a, 13a-b]. The assessment of COX-1/COX-
2 IC50 in vitro values describes an experimental COX-isoenzyme 
selectivity which mirrors the chemical features of the different 
NSAIDs. However, it has been shown that COX-2 selectivity of 
NSAIDs is a continuous variable and there is not a cut-off value of 
COX-1/COX-2 IC50 ratio which separates tNSAIDs from coxibs 
[11, 12a]. Thus, the tNSAID diclofenac shows a COX-2 in vitro 
selectivity comparable to that of the coxib celecoxib [12a]. The 
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whole blood assay also permit to estimate “achieved” COX-
isoenzyme selectivity in humans when the drugs are administered at 
therapeutic doses (this is called COX-2 selectivity ex vivo). The 
“achieved ” COX selectivity is obtained by assessing the degree of 
inhibition of COX-1 and COX-2 by circulating drug concentrations. 
Achieved selectivity of NSAIDs varies as a consequence of the 
administered dose [12a]. The assessment of COX-2 selectivity ex 
vivo allows to predict the clinical outcomes (both therapeutic and 
toxic effects) when these drugs are administered to humans [12a].  
NSAIDs are characterized by different COX-1/COX-2 selectiv-
ity, and different pharmacokinetic and toxicological profiles 
[12a,b]. 
Reduced incidence of serious gastrointestinal (GI) adverse ef-
fects compared to tNSAIDs has been demonstrated for 2 highly 
selective COX-2 inhibitors [e.g. rofecoxib (8) and lumiracoxib 
(12)] in large randomized clinical trials (RCTs) [14 a,b]. This was a 
proof of concept that sparing COX-1 in the GI tract and possibly in 
platelets translates to a safer GI profile [11]. In fact, COX-1 is con-
stitutively expressed in the stomach and platelets [15], whereas 
COX-2 does not appear to be expressed or is expressed at very low 
levels. However, both COX-isozymes are a source of cytoprotective 
prostanoids [16a]. COX-1-derived prostanoids (mainly PGE2) are 
involved in the constitutive defense mechanism operating in 
physiological conditions [11]. In contrast, endogenous PGE2 de-
rived from COX-2 plays an important part in the spontaneous heal-
ing of gastric ulcers [16a-d]. This is supported by clinical data 
showing that coxibs are still associated with a small risk of upper 
gastrointestinal bleed (UGIB), though smaller than that caused by 
tNSAIDs [14 a,b]. Interestingly, agents with a coincident inhibition 
of both COX-1 and COX-2 were the ones associated with the high-
est relative risk of UGIB [17]. The use of tNSAIDs at the lowest 
effective dose may be a strategy to reduce GI toxicity. In fact, it 
was found that low-dose ibuprofen (a nonselective NSAID) has 
comparable UGIB risk as rofecoxib (8), and celecoxib (6)[17].  
Despite dose reduction is recommended to reduce GI toxicity, it 
has to be claimed that this strategy may reduce their clinical effi-
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Chart 1. Traditional Nonsteroidal Anti-inflammatory Drugs.  
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Chart 2. The Coxib Family. 
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cacy. The assessment of a biomarker which may predict the anti-
inflammatory and analgesic effects of NSAIDs, such as the evalua-
tion of whole blood COX-2 inhibition, showed that circulating drug 
concentrations which inhibit COX-2 by 80% are appropriate to 
cause clinical efficacy (analgesia) [12a, 18].  
An important clinical issue associated with the use of NSAIDs, 
is the possible increased risk of cardiovascular side-effects, such as 
thrombotic events, hypertension and heart failure. It has been re-
cently evidenced that the use of NSAIDs (both coxibs and 
tNSAIDs) in the general population is associated with a 35% in-
creased risk of non fatal myocardial infarction (MI) [relative risk 
1.35, (95% CI), 1.23 to 1.48] [19]. The excess risk increased with 
increasing treatment duration and daily dose. Using a translational 
medicine approach, i.e. from proof of concept in cells and experi-
mental animals to studies in humans, it was possible to show that 
inhibition of COX-2-dependent prostacyclin is the most plausible 
mechanism involved in cardiovascular hazard by NSAIDs. COX-2 
is among the endothelial genes upregulated
 
by uniform laminar 
shear stress (LSS), characteristically associated
 
with atherosclerotic 
lesion-protected areas [10c]. We have recently enlightened a central 
role played by LSS-induced COX-2–dependent prostacyclin in 
restraining endothelial inflammation [20]. Thus, inhibition of COX-
2-dependent prostacyclin might
 
contribute to acceleration of 
atherogenesis in patients taking
 
tNSAIDs and
 
NSAIDs selective for 
COX-2 [20].  
In mice, it has been demonstrated that endothelial COX-2 de-
pendent prostacyclin modulates thrombosis induced in vivo by pho-
tochemical injury to the vasculature [21] using different ap-
proaches, i.e. the administration of the COX-2 selective inhibitor 
5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl)phenyl-
2(5H)-furanone (DFU), deletion of PGI2 receptor (IP) and specific 
deletion of COX-2 in endothelial cells. 
Single-nucleotide polymorphisms (SNPs) within the IP have 
been identified and, interestingly, the R212C variant is associated 
with defective prostacyclin signalling, i.e. reduced generation of the 
second messenger c-AMP after activation of the receptor [22]. Im-
portantly, Arehart et al. [22] have shown that patients who were 
carriers of the SNP R212C were associated with increased cardio-
vascular disease and events, analogously to COX-2 inhibition. 
The increased incidence of thrombotic events associated with 
profound inhibition of COX-2-dependent prostacyclin by coxibs 
and tNSAIDs can be mitigated, even if not obliterated, by a com-
plete suppression of platelet COX-1 activity [23 a,b].  
However, most tNSAIDs and coxibs are not able to inhibit al-
most completely and persistently platelet COX-1 activity to deter-
mine an in vivo inhibition of platelet function [23a,b]. This explains 
why they shared comparable cardiovascular toxicity [19]. Among 
all NSAIDs, a CV safer drug is naproxen and this is due to its 
pharmacodynamics and pharamcokinetics, i.e. the drug inhibits 
profoundly platelet COX-1 activity and this effect persists through-
out dosing interval due to its long half-life (approximately 17 
hours) [19]. However, naproxen is one of the more toxic drug for 
the GI system due to its profound inhibitory effect for the GI 
prostanoids. 
We found that the extent of inhibition of COX-2–dependent 
prostacyclin may represent an independent key determinant of the 
increased risk of MI among NSAIDs , which does not affect platelet 
function, a property shared by coxibs and most tNSAIDs, and that 
the assessment of whole blood COX-2 might represent a surrogate 
end-point to predict the cardiovascular risk of these drugs [19]. 
However, appropriate clinical studies should be performed to verify 
this preliminary finding. 
Reduction of the dose is recommended and presumably will 
limit the number of patients exposed to a cardiovascular hazard by 
NSAIDs. It will not, however, eliminate the risk on an individual 
level because there is a marked variability in how different people 
react to these drugs, based, at least in part, on their genetic back-
ground [24]. 
The planning for novel NSAIDs with a different chemical struc-
ture should be important on the light of marked variability in the 
response to these drugs in humans both for the therapeutic effects 
and for the toxic effects.  
Thus, we started a wide research programme,
 
aimed at discover-
ing new pyrrole-containing anti-inflammatory agents and focused 
on the synthesis of 1,5-diarylpyrrole-3-acetic ketoesters, acids, 
esters, and ethers, as new COX-2 selective inhibitors in which the 
pyrroleacetic and vicinal diaryl heterocyclic moieties were reminis-
cent of indometacin (5) and of the coxib family, respectively [25a-
h]. The results obtained by us on this topic are reported below. 
ETHER, ESTER AND ACID DERIVATIVES OF THE 1,5-
DIARYLPYRROLE SCAFFOLD 
Having a look at the chemical structures reported in Chart 2, 
with the exclusion of etoricoxib (11) and lumiracoxib (12), it could 
be recognized how diaryl-substituted penta-atomic heterocylcles 
could be particularly well shaped for originating potent and selec-
tive COX-2 inhibitors. Indeed, the diaryl substitution decoration 
was found to be an essential feature for generating potent selective 
inhibitors able to fulfil all the required interactions [26].  
The diaryl substitution pattern can be also recognized in a num-
ber of penta-atomic heterocylcles, particularly imidazoles and pyra-
zoles, for example, in the class of Mitogen-activated protein (MAP) 
kinase inhibitors [27a,b]. Liverton and co-workers reported interest-
ing issues on diarylpyrroles as p38 kinase inhibitors. In particular, 
the issues showed that the presence of two aryl moieties on adjacent 
positions was a crucial parameter in determining activity [28]. As 
reported by McIntyre, the presence of a central ?-electron excessive 
aromatic heterocycle bearing two aryls on adjacent positions is the 
main feature for identifying kinases inhibitors [29]. The diaryl-
heterocyclic motif can also be found when dealing with cannabi-
noid receptor modulators. Rimonabant, a diaryl pyrazole, is the first 
prototype of this class of CB1 receptor modulators but there are a 
lot of closely related molecules which have been submitted to clini-
cal testing [30]. In order to decrease the possibility of unwanted 
potentially unsafe interaction with other targets (i.e. kinases) and to 
optimize absorption, distribution, metabolism, and excretion 
(ADME) characteristics, we chose the pyrrole nucleus as the core 
heterocycle. The pyrrole nucleus and properly substituted pyrroles 
are moieties present in several natural and safe substances [31]. 
This heterocycle is quite stable from a metabolic standpoint, it does 
not give rise to reactive intermediates by metabolic activation and it 
is endowed with a suitable hydrophilicity. As drugs, pyrroles have 
been described for various uses including treatment of inflamma-
tion, pain and cardiovascular diseases. Khanna and co-workers 
described a series of diaryl-pyrroles as COX-2 selective inhibitors. 
Both in vitro and in vivo issues suggested that the decorated central 
pyrrole was crucial for activity and the enzymatic properties of such 
a class of derivatives was closely dependent on the substitution 
pattern [32]. On these grounds, at the very beginning of our re-
search programme aimed at discovering new pyrrole-containing 
antiinflammatory agents, we focused our attention on the synthesis 
of 1,5-diarylpyrrole-3-acetic acids and esters (12-43) (Chart 3) 
[25a,b,f]. These compounds were characterized by: i) a p-
methylsulfonylphenyl substituent, responsible for the COX-2 selec-
tive inhibition [present in rofecoxib (8) and etoricoxib (11)] at C5 
(12-32) or N1(33-43) of the pyrrole nucleus; ii) a second phenyl 
ring decorated with different groups such as H, 3-F, 4-F, 3,4-F2, 4-
CF3, 4-OCH3 and 4-CH3; iii) a ketoacid, ketoester, acetic acid and 
acetic ethyl ester chain at C3. 
A structure-activity relationship (SAR) analysis of compounds 
12-43, supported by molecular docking simulations of these inhibi-
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tors within the COX-2 binding site,
 
allowed us to rule out several 
considerations: i) the position of the p-methylsulfonylphenyl sub-
stituent was very important for activity (in general compounds 12-
32 being more active than 33-43); ii) surprisingly, the acetic ethyl 
ester chain at C3 of the pyrrole ring led to compounds more active 
than the corresponding acids and ketoesters; iii) substituents and 
substitution pattern on the phenyl ring at N1 influenced activity in 
the following order: 3-F = 4-F > 3,4-F2 > 4-O CH3 > H > 4-CF3 > 
4-CH3 [25a,b.f]. 
On the basis of these results, carrying on the project we planned 
the synthesis of new derivatives (44-49) [25c,f]. Thus, keeping the 
most convenient fluorine substitution (namely the 3-F substituent at 
the N1 phenyl ring), as well as the 4-methoxyphenyl and the 3,4-
difluorine-phenyl groups and an unsubstituted phenyl ring at posi-
tion 1 of the pyrrole, we introduced a hydroxyl or an ethoxyl chain 
at the methylene of the C3 alkyl chain (leading to the corresponding 
chiral alcohol and ether derivatives 44a-c-49a-c, respectively, Chart 
3) to evaluate the presence of any kind of stereoselective interac-
tion at the enzyme’s active site and to check the possible variation 
of activity induced by different enantiomers [25c,f]. Enantiomeri-
cally pure samples were obtained, at mg-scale, by high performance 
liquid chromatography (HPLC) on the amylose-based Chiralpak IA 
chiral stationary phase. In particular, the absolute configuration of 
(-)-44c was determined by single-crystal X-ray diffraction analysis 
[25d]. The findings of X-ray structure analysis allowed us to assign 
unambiguously the (R)-configuration to the (-)-44c enantiomer. 
Then, the stereochemistry of remaining pyrrole derivatives was 
empirically assigned by circular dichroism spectroscopy. All the 
enantiomers showed a very good activity, even though, in general 
they proved to be less active than corresponding previously synthe-
sized derivatives lacking a stereogenic center at the ?-position of 
the side chain [25c,f]. 
In order to expand the knowledge about the SAR of this class of 
compounds, the search for further functionalizations on the pyrrole 
nucleus spurred us to transform 1,5-diarylpyrrole-3-acetic esters 
into the hitherto unknown 3-alkoxyethyl ethers 50-58 (Chart 3) 
[25e,f]. Biological evaluation of these compounds showed that in 
the class of 1,5-diarylpyrrole-3-acetic alkylesters, the replacement 
of the acetic ester moiety with an alkoxyethyl group still led to new, 
highly selective and potent COX-2 inhibitors [25e,f].  
Finally, we pursued the synthesis and the biological activity of 
derivatives 59-66, in which longer side chains were introduced at 
C3 on the basis of the hypothesis that such chains could better in-
teract with hydrophobic residues of the receptor’s carboxylate 
pocket. In particular, compounds 59-66, bearing an i-propyl or a n-
butyl ester function, a N1 phenyl ring substituted with various 
moieties previously found to be important for activity (namely, 3-F, 
3,4-diF, 4-OCH3) and a C5 p-methylsulfonyl phenyl moiety, 
showed outstanding activities.  
BIOLOGICAL AND PHARMACOLOGICAL EVALUATION 
All compounds were subjected to biological evaluation through 
in vitro testing (J774 Murine Macrophage Assay) and the results are 
reported in Tables 1, 2, 3 and 4. The in vitro estimation of the title 
compounds was performed to assess their inhibitory activity on 
both COX-1 and COX-2, hence their selectivity toward the latter. In 
vitro activity is defined as the concentration required to inhibit the 
activity of the isoenzymes, while selectivity toward COX-2, re-
ferred to as Selectivity Index (SI), is described as the ratio of the 
concentrations required to inhibit the activity of both isoenzymes by 
50% (IC50) (i.e. IC50(COX-1)/ IC50(COX-2)]. The in vitro issues 
showed that all compounds were very selective and that, in general, 
the activity was a function of the substitution pattern present on the 
pyrrole ring. More specifically the compounds bearing the p-
methylsulfonylphenyl group at position 5 of the pyrrole nucleus 
(compounds 12-32 and 44-66), could be considered the most selec-
tive, probably because of a more efficacious interaction with the 
enzyme active site with respect to the corresponding N1 p-
methylsulfonylphenyl derivatives (compounds 33-43). Compounds 
showing an interesting biological profile were chosen and further 
investigated through pharmacological experimentations. Thus, 
N
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Chart 3. Structures of Compounds 12-66.  
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Table 1. Chemical Structures and In Vitro COX-1 and COX-2 Inhibitory Activity of Compounds 12-43 by Using Cell-Based Assay 
 
N
X
COOR''
R'
R  
 
Compd R R’ R
’’
 X 
COX-1 IC50 
(μM)a 
COX-2 IC50 
(μM)a 
% of COX-2  
Inhibition (10μM) 
% of COX-2 
Inhibition (1μM) 
COX-1/ 
COX-2 
(SI) 
12 H 4-SO2CH3 C2H5 CO >100 4.3 54 43 >23 
13 4-CH3 4-SO2CH3 C2H5 CO >100 1.9 77 33 >92 
14 4-CF3 4-SO2CH3 C2H5 CO >100 9.9 51 33 >10 
15 4-F 4-SO2CH3 C2H5 CO >100 11.0 51 19 >9 
16 3-F 4-SO2CH3 C2H5 CO >100 0.90 75 55 >100 
17 3,4-F2 4-SO2CH3 C2H5 CO >100 8.4 55 8 >12 
18 4-OCH3 4-SO2CH3 C2H5 CO >100 0.94 70 59 >100 
19 H 4-SO2CH3 H CH2 >100 1.0 100 43 >100 
20 4-CH3 4-SO2CH3 H CH2 >100 0.43 100 74 >200 
21 4-CF3 4-SO2CH3 H CH2 >100 0.11 100 69 >900 
22 4-F 4-SO2CH3 H CH2 >100 ND
b NDb NDb NDb 
23 3-F 4-SO2CH3 H CH2 >100 0.028 96 89 >3500 
24 3,4-F2 4-SO2CH3 H CH2 47 0.26 98 70 38 
25 4-OCH3 4-SO2CH3 H CH2 >100 0.17 90 62 >580 
26 H 4-SO2CH3 C2H5 CH2 >100 0.04 84 79 >2500 
27 4-CH3 4-SO2CH3 C2H5 CH2 >100 0.48 81 67 >208 
28 4-CF3 4-SO2CH3 C2H5 CH2 >100 0.06 87 80 >1600 
29 4-F 4-SO2CH3 C2H5 CH2 >100 0.010 100 100 >10000 
30 3-F 4-SO2CH3 C2H5 CH2 >100 0.010 100 91 >10000 
31 3,4-F2 4-SO2CH3 C2H5 CH2 >100 0.020 100 87 >5000 
32 4-OCH3 4-SO2CH3 C2H5 CH2 >100 0.026 90 87 >4000 
33 4-SO2CH3 H C2H5 CO >100 ND
b 30 0 NDb 
34 4-SO2CH3 4-CH3 C2H5 CO >100 ND
b 25 0 NDb 
35 4-SO2CH3 4-CF3 C2H5 CO >100 ND
b 34 30 NDb 
36 4-SO2CH3 4-F C2H5 CO >100 ND
b 12 0 NDb 
37 4-SO2CH3 3,4-F2 C2H5 CO >100 ND
b 29 0 NDb 
38 4-SO2CH3 4-OCH3 C2H5 CO >100 ND
b 49 21 NDb 
39 4-SO2CH3 H C2H5 CH2 >100 ND
b 27 0 NDb 
40 4-SO2CH3 4-CH3 C2H5 CH2 >100 1.96 79 33 >50 
41 4-SO2CH3 4-CF3 C2H5 CH2 >100 ND ND ND ND 
42 4-SO2CH3 4-F C2H5 CH2 >100 0.40 75 50 >250 
43 4-SO2CH3 4-OCH3 C2H5 CH >100 0.55 78 59 >200 
celecoxib     5.1 0.079 95 80 65 
aResults are expressed as the mean (n=3) of the % inhibition of PGE2 production by test compounds with respect to control samples. 
bNot Determined. 
selectivity of compounds was determined by the human whole 
blood assay [13a,b], which permit to estimate the “achieved” COX 
inhibition ex vivo by circulating drug levels. Results indicated a 
dramatic change in terms of COX selectivity in these experimental 
conditions. Finally, to assess in vivo anti-inflammatory and analge-
sic activity, three different tests (rat paw pressure, rat paw oedema 
and abdominal constriction, Tables 5, 6, and 7, respectively) were 
performed. The submitted compounds, administered at a dose rang-
ing from 5 to 20 mg/kg p.o., showed very good activities against 
carrageenan-induced hyperalgesia 30 min after administration. The 
analgesic activities at this time were very similar to that obtained 
with celecoxib (10 mg/kg p.o.) (Table 5). Good activity profiles 
were displayed against carrageenan-induced rat paw oedema, with 
almost complete remission 1h after the administration (20 mg/kg 
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Table 2. Chemical Structures and In Vitro COX-1 and COX-2 Inhibitory Activity of Compounds 44-49 by Using Cell-Based Assay 
 
N
COOEt
R
R'
H3CO2S
 
 
Compd R X 
COX-1 IC50 
(μM)a 
COX-2 IC50 
(μM)a 
% of COX-2  
Inhibition (10μM) 
% of COX-2 
Inhibition (1μM) COX-1/ COX-2 (SI) 
(+/-)44a H OH >100 0.30 100 78 >600 
(+)-(S)44b H OH >100 0.18 92 79 >550 
(-)-(R)44c H OH >100 0.15 92 86 >650 
(+/-)45a 3-F OH >100 0.12 100 70 >800 
(+)-(S)45b 3-F OH >100 1.10 84 56 >90 
(-)-(R)45c 3-F OH >100 0.075 92 86 >1300 
(+/-)46a 4-OCH3 OH >100 0.12 100 82 >800 
(+)-(S)46b 4-OCH3 OH >100 0.079 100 88 >1200 
(-)-(R)46c 4-OCH3 OH >100 0.15 93 86 >650 
(+/-)47a H OC2H5 >100 0.18 100 90 >800 
(+)-(S)47b H OC2H5 >100 0.10 100 81 >1000 
(-)-(R)47c H OC2H5 >100 0.14 86 77 >700 
(+/-)48a 3-F OC2H5 >100 0.10 100 74 >1000 
(+)-(S)48b 3-F OC2H5 >100 0.25 100 86 >400 
(-)-(R)48c 3-F OC2H5 >100 0.81 100 73 >100 
(+/-)49a 4-OCH3 OC2H5 >100 0,13 ND
b NDb >800 
(+)-(S)49b 4-OCH3 OC2H5 >100 0.14 100 100 >700 
(-)-(R)49c 4-OCH3 OC2H5 >100 0.09 100 87 >1100 
celecoxib   5.1 0.079 95 80 65 
aResults are expressed as the mean (n=3) of the % inhibition of PGE2 production by test compounds with respect to control samples. 
bNot Determined. 
p.o) (Table 6). Moreover, a dose-dependent anti-nociceptive activ-
ity was observed in the abdominal constriction test (Table 7). The 
in vitro test highlighted the acetic esters derivatives 30 and 59 as 
the most active compounds [25b,g]. These molecules displayed 
excellent IC50 values (in the range of nanomolar concentrations) and 
selectivity indexes higher than those shown by reference com-
pounds (up to 10000). Moving the fluorine substituent of compound 
30 from the meta to the para-position of the N1 phenyl ring, as for 
compound 29, the activity was maintained nearly by, while the 
simultaneous presence of two fluorine atoms at the meta and para 
positions (compound 31) led to a slight reduction of both activity 
and selectivity (Table 1) [25b]. SAR data indicated that the p-
methylsulfonylphenyl group at the C5 phenyl ring and a fluorine 
substituent at the N1 phenyl ring are cooperative determinants for 
both potent and selective COX-2 inhibition. The analysis of bulky 
compounds revealed that the ester function, present in compound 
59, could be responsible for the potency and selectivity performed 
by this class of hindered compounds: this led to the suggestion that 
an increase of hindrance at C3 could translate to activity enhance-
ment [25g]. The exception is performed by the fluorinated series of 
compounds, whose ethyl ester derivatives seem to be more selective 
than the bulkier analogues (i-propyl and n-butyl derivatives). Since 
the hydrolysis of the ester can occur at least to some extent in vivo, 
ester compounds 26-32 and 59-66 were evaluated in comparison 
with the corresponding acid (19-25) [25g]. In general the ester de-
rivatives proved to be more effective and selective toward COX-2 
with respect to acid derivatives and only in the case of 3-F phenyl 
substituted derivatives the acid compound 23 and the esters com-
pounds 30, 61 and 62 displayed closer potencies. The biological 
evaluation also affords to outline that the activity characterizing the 
acetic compounds 26-32 rapidly decreases when a carbonyl group is 
introduced at C3, making the side chain to be sterically frozen, to 
obtain the glyoxylic compounds 12-18 [25a,b]. Compounds 44-49, 
characterized by the insertion of a stereogenic carbon at position 3 
of the pyrrole core, were synthesized in order to evaluate the pres-
ence of stereoselective interactions at the enzyme’s active site. In 
vitro cell-based assay showed IC50 values toward COX-2 in the 
submicromolar concentration [with the only exception of (+)-(S)-
45b], while compounds were all inactive toward COX-1 at the 
maximum tested dose (100 ?M). All the enantiomers showed a very 
good activity, even though, in general they proved to be less active 
than corresponding derivatives lacking a stereogenic center at the 
C3 side chain ?-position. Biological evaluation of 3-alkoxyethyl 
ether compounds 50-58 showed that the replacement of the acetic 
ester moiety with an alkoxyethyl group produced a significant dif-
ference in terms of inhibitory activity. Actually, compound 53 is 
more potent than the corresponding ester compounds 26 but in gen-
eral 3-alkoxyethyl ethers are less potent than the above-cited esters 
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Table 3. Chemical Structures and In Vitro COX-1 and COX-2 Inhibitory Activity of Compounds 50-58 by Using Cell-Based Assay 
 
N
H3CO2S
OR'
R  
 
Compd R R
’
 
COX-1 IC50 
(μM)a 
COX-2 IC50 
(μM)a 
% of COX-2  
Inhibition (10μM) 
% of COX-2  
Inhibition (1μM) 
COX-1/ COX-2 
(SI) 
50 H CH3 >100 0.048 ND
b NDb >2083 
51 F CH3 >100 0.018 ND
b NDb >5555 
52 CF3 CH3 >100 0.049 ND
b NDb >2040 
53 H C2H5 >100 0.015 ND
b NDb >6666 
54 F C2H5 >100 0.047 ND
b NDb >2127 
55 CF3 C2H5 >100 0.085 ND
b NDb >1176 
56 H n-C3H7  >100 0.018 ND
b NDb >5555 
57 F n-C3H7 >100 0.030 ND
b NDb >3333 
58 CF3 n-C3H7 >100 0.110 ND
b NDb >909 
celecoxib   5.1 0.079 95 80 65 
aResults are expressed as the mean (n=3) of the % inhibition of PGE2 production by test compounds with respect to control samples. 
bNot Determined. 
 
Table 4. Chemical Structures, and In Vitro COX-1 and COX-2 Inhibitory Activity of Compounds 59-66 by Using Cell-Based Assay 
 
N
COOR'
R
H3CO2S
 
 
Compd R R
’
 
COX-1 IC50 
(μM)a 
COX-2 IC50 
(μM)a 
% of COX-2 Inhi-
bition (10μM) 
% of COX-2 Inhi-
bition (1μM) COX-1/ COX-2 (SI) 
59 H i-C3H7 >100 0.0073 100 100 > 13600 
60 H n-C4H9 >100 0.014 88 85 > 7100 
61 3-F i-C3H7 >100 0.043 91 85 > 2300 
62 3-F n-C4H9 >100 0.024 100 87 > 4100 
63 3,4-F2 i-C3H7 >100 0.021 90 85 > 4700 
64 3,4-F2 n-C4H9 >100 0.03 90 86 > 3300 
65 4-OCH3 i-C3H7 >100 0.022 100 88 > 4500 
66 4-OCH3 n-C4H9 >100 0.038 92 89 > 2600 
celecoxib   5.1 0.079 95 80 65 
aResults are expressed as the mean (n=3) of the % inhibition of PGE2 production by test compounds with respect to control samples. 
[25e]. These data can be easily explained if we take into considera-
tion the different stereoelectronic properties of the acetic ester chain 
with respect to the alkoxyethyl moiety.
 
On the other hand, it is less 
clear how the alkoxyethyl derivatives, even in the absence of the 
carbonyl group, are able to exert highly selective and potent COX-2 
inhibitory activities. The human whole blood assay indicated that 
the issues gained through the cell-based assay are in some extent 
reversed. In fact, celecoxib showed a COX-1/COX-2 IC50 ratio of 
23 in the human whole blood assay (Table 8), whereas a COX-
1/COX-2 IC50 ratio 64.5 was found in the cell-culture test. The 
reversion is much more meaningful when considering compound 
30: in the human whole blood its COX-1/COX-2 IC50 ratio was 
about 9.7 while it showed a >10000 ratio in vitro (Tables 1 and 8). 
The discrepancy between the results obtained by using the human 
whole blood assay and those found in the cell-based assay could be 
due to a different inhibitor sensitivity showed by the mouse and 
human COX isoenzymes, as already reported for other anti-
inflammatory compounds. Thus, a dramatic loss in COX inhibition 
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Table 5. Effect of Selected Active Compounds on Hyperalgesia by Carrageenan in the Rat Paw-Pressure Test
a 
 
Paw pressure (g) 
Pre-treatment Treatment 
Before treatment 30 min 60 min 120 min 
saline 
carrageenan 
Saline 
Saline 
62.0±4.3 
61.9±5.1 
62.6±5.2 
38.7±5.3 
63.5±4.6 
35.8±4.5 
64.2±5.2 
40.1±5.0 
carrageenan 19 63.1±3.9 48.6±4.3 51.8±3.6 41.6±3.7 
carrageenan 23 62.7±4.2 54.8±3.7 55.2±3.8 43.1±3.9 
carrageenan 24 59.2±3.4 58.3±3.4 54.1±4.4 48.6±3.4 
carrageenan 25 61.2±3.6 52.3±3.7 39.8±4.1 36.2±3.2 
carrageenan 30 61.7±3.9 55.2±3.6 49.8±4.1 43.4±4.9 
carrageenan (+/-)-45a 59.6±2.8 54.8±3.8 45.2±4.60 47.5±4.6 
carrageenan 53 60.5 ± 4.3 59.6 ± 4.7 53.8 ± 4.2 49.1 ± 5.4 
carrageenan 56 59.2 ± 5.2 56.3 ± 5.6 59.4 ± 5.1 50.6 ± 5.3 
carrageenan 57 63.5 ± 4.3 52.4 ± 5.2 56.8 ± 4.9 52.7 ± 4.0 
carrageenan 59 60.8 ± 4.3 56.2 ± 4.8 51.8 ± 5.3 48.8 ± 3.7 
carrageenan 60 57.5 ± 3.7 52.5 ± 4.9 46.3 ± 5.3 42.6 ± 3.8 
carrageenan 61 63.2 ± 3.8 59.5 ± 5.4 57.9 ± 4.1 45.2 ± 4.3 
carrageenan 62 62.4 ± 3.2 49.7 ± 4.1 46.9 ± 5.5 45.2 ± 4.8 
carrageenan 63 64.8 ± 3.8 59.5 ± 2.9 52.3 ± 4.9 58.3 ± 3.4 
carrageenan 64 58.3 ± 3.6 52.7 ± 5.0 59.2 ± 6.3 56.6 ± 4.5 
carrageenan 65 58.6 ± 4.1 51.0 ± 5.5 56.7 ± 4.4 41.7 ± 4.1 
carrageenan 66 60.5 ± 3.0 53.4 ± 4.8 51.4 ± 5.0 50.8 ± 5.2 
carrageenan celecoxib 62.7±3.9 56.5±3.8 58.2±4.4 55.2±5.1 
aAll compounds were administered at the dose of 20 mg kg-1 p.o. Carrageenan (100 μl, 1%) was administered i.pl. 4h before test. Test was performed 30 min after the compound 
injection. There were 5-6 rats per group. P<0.01 versus the corresponding carrageenan treated rat. 
 
Table 6. Effect of Selected Active Compounds on Carrageenan-Induced Oedema in the Rat Paw-Pressure Test
a 
 
Pre-treatment treatment Before treatment 60 min after 
saline saline 1.25 ± 0.09 1.29 ± 0.10 
carrageenan saline 1.22 ± 0.08 2.33 ± 0.08 
carrageenan 19 1.23 ± 0.10 1.86 ± 0.07 
carrageenan 23 1.28 ± 0.05 1.35 ± 0.09 
carrageenan 24 1.32 ± 0.10 1.42 ± 0.09 
carrageenan 25 1.27± 0.08 1.81± 0.12 
carrageenan 30 1.24±0.11 1.29±0.14 
carrageenan (+/-)-45a 1.37±0.12 1.40±0.13 
carrageenan 53 1.29 ± 0.10 1.37±0.11 
carrageenan 56 1.32 ± 0.06 1.41 ± 0.14 
carrageenan 57 1.25 ± 0.09 1.45 ± 0.12 
carrageenan 59 1.29 ± 0.09 1.26 ± 0.12 
carrageenan 60 1.31 ± 0.10 1.68 ± 0.15 
carrageenan 61 1.17 ± 0.11 1.31 ± 0.09 
carrageenan 62 1.35 ± 0.09 1.71 ± 0.11 
carrageenan 63 1.29 ± 0.10 1.39 ± 0.12 
carrageenan 64 1.23 ± 0.08 1.52 ± 0.09 
carrageenan 65 1.16 ± 0.07 1.41 ± 0.08 
carrageenan 66 1.33 ± 0.08 1.45 ± 0.14 
carrageenan celecoxib 1.28±0.14 1.33±0.10 
aAll compounds were administered at the dose of 20 mg kg-1 p.o. Carrageenan (100 μl, 1%) was administered i.pl. 4h before test. Test was performed 30 min after the compound 
injection. There were 5-6 rats per group. P<0.01 versus the corresponding carrageenan treated rat. 
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Table 7. Effect of Selected Active Compounds in the Mouse Abdominal Constriction Test (Acetic Acid 0.6%) 
 
 
Treatment
a
 number of mice 
dose (p.o. mg kg
-1
) number of writhes 
CMC 20  31.4 ± 4.3 
19 11 10 27.3 ± 3.2 
19 10 20 22.2 ± 2.9 
23 9 10 31.6 ± 3.2 
23 8 20 17.5 ± 3.1 
24 12 10 29.3 ± 3.0 
24 10 20 15.7 ± 2.6 
25 10 10 30.9± 3.3 
25 10 20 21.8± 2.1 
30 10 10 28.9 ± 23.9 
30 7 20 15.7 ± 3.6 
(+/-)-45a 8 10 26.3 ± 3.6 
(+/-)-45a 8 20 16.1 ± 2.7 
53 10 10 26.5 ± 3.7 
53 8 20 11.4 ± 3.6 
56 9 10 27.43 ± 4.1 
56 9 20 13.6 ± 4.2 
57 10 10 38.1 ± 3.4 
57 10 20 16.7 ± 3.5 
59 8 1 33.6 ± 3.0 
59 8 5 28.5 ± 3.3 
59 8 15 25.5 ± 2.8 
60 8 20 23.9 ± 3.4 
61 12 5 39 .5 ± 3.8 
61 9 20 17.7 ± 2.9 
62 8 20 24.4 ± 4.1 
63 10 5 35 .1 ± 4.6 
63 12 20 21.5 ± 3.9 
63 10 40 19.8 ± 3.2 
64 12 5 34.4 ± 3.5 
64 30 20 13.7 ± 4.0 
65 11 5 42.2 ± 4.0 
65 12 20 18.0 ± 3.5 
66 8 10 21.6 ± 2.9 
66 10 20 15.9 ± 3.3 
celecoxib 12 10 14.2 ± 2.3 
aAll drugs were administered per os 30 min before test.  
potency and drop in selectivity when using the human whole blood 
assays are shared with other selective COX-2 inhibitors such as 
valdecoxib [33,34], etoricoxib [33,34], lumiracoxib [35] and ro-
fecoxib [36,37] as well as (t)NSAID such as nimesulide [33,38] and 
meloxicam [39,40].  
In vivo tests highlighted an increase of activity along with the 
increase of hindrance of C3 side chain. In the rat paw-pressure test, 
the activities of esters compounds 59-66 proved to be better than 
those of corresponding acid compounds 19 and 23-25. All these 
bulkier esters proved to be very effective and long lasting, being, in 
such a test, a relevant analgesia still present 2 hours after admini-
stration. Conversely, the corresponding acid compounds 19 and 23-
25 highlighted a remarkable lower activity especially after 2 hours, 
with the exception of compound 24. Ethyl esters (compounds 30 
and (+/-)-45a) displayed an activity which tended to fade at longer 
time (1h), disappearing almost completely 2 h after administration. 
3-Alkoxyethyl-ether (compounds 53, 56 and 57) showed activities 
comparable to those reported for bulky esters (compounds 59-66). 
In parallel, a very good activity was demonstrated by all subjected 
compounds against carrageenan-induced rat paw oedema (Table 3), 
with a complete remission 1 h after the administration (20 mg/kg 
p.o.). In the abdominal constriction test all compounds were able to 
reduce the number of wrights in a statistically significant manner at 
a dose of 20 mg/kg p.o. The issues regarding the in vivo profiles 
characterizing the ester derivatives can be better understood when 
taking into account their metabolic features. Preliminary studies 
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were made on derivative 59 and its related acid 19 to underline their 
pharmacokinetics. The results of this study showed that compound 
59 was characterized by a 42% of relative oral bioavailability and 
by a high clearance value. After both oral and endovenous admini-
stration of 59, the presence of the acid 19 was detected thus under-
lining that hydrolysis of the ester moiety did occur. It was also ob-
served that the size of metabolism was independent by the route of 
administration [25g]. Hence, the instability of the ester moiety 
could in some extent confirm what found by the in vivo studies: 
indeed, the long-lasting pharmacological activity characterizing 
bulkier esters could be representative for a prodrug-like system, in 
which the pharmacological aspects of the ester are dependent on 
both the activity related to the ester itself and the acid which is con-
tinuously released in vivo, as displayed by pharmacokinetics. This 
could also account for the longer effect characterizing bulky esters 
(Table 5) in relation to ethyl ones. In fact, the former are character-
ized by a relative slow metabolism (hence a slower generation of 
the related acid) due to the hindered esterified moiety that leads to 
an enhanced pharmacological effect. Nevertheless, the composite 
metabolic pathway that characterize esters represents a great chal-
lenge in terms of drug development. Indeed, both pharmacokinetics 
and in vivo tests did not disclose the actual agent responsible for 
activity: we are aware about the fact that both the acid and the ester 
are available for promoting the pharmacological effect, but we do 
not know the real extent of each. Furthermore, we could hypothe-
size that after in vivo administration the ester would be directly 
involved in the interaction with the biophase but we are not able to 
demonstrate it with the available data. To enlarge our knowledge 
about the importance of a C3 side chain on the pyrrole core of our 
compounds we will follow a bioisosteric replacement of the ester 
moiety which proved to be quite sensitive to hydrolysis (both 
chemical and enzyme-dependent). This kind of replacement will 
allow us to correlate the obtained results with the 3-alkoxyethyl-
ether compounds, which share the same scaffold with the ester de-
rivatives but are not sensitive to the same metabolic route (hydroly-
sis), in order to understand if the integrity of the C3 side chain is a 
crucial aspect for activity or if different substitution patterns can be 
brought about to obtain the pharmacological effect.  
COMPUTATIONAL STUDIES 
Cyclooxygenase inhibitors belonging to the coxib family (such 
as celecoxib and SC-558) show a similar binding mode with the 
two isoforms, in agreement with that recently reported in the litera-
ture [41]. The differences involve in particular, Arg513 of COX-2, 
that interacts by a hydrogen bond with one of the sulfonamide oxy-
gen atoms of SC-558 (as found in the complex coded 6cox in the 
protein data bank, Fig. 1, upper panel) [42], and the corresponding 
His513 of COX-1, that was unable to contact celecoxib (entry 3kk6, 
Fig. 1, lower panel). Moreover, reciprocal orientation between 
Val434 and Phe518 of COX-2 is significantly different from that of 
Ile434 and Phe518 of COX-1 [41]. 
Two computational approaches were applied to pyrrole com-
pounds, based on molecular docking/structural optimization and on 
the generation of Grid maps for different probes. Results from cal-
culations led to the identification of a binding mode for the new 
inhibitors, to the rationalization of their major structure-activity 
relationships, and, finally, to the suggestion of structural modifica-
tions to obtain new derivatives with higher affinity for COX-2. 
To study the binding mode of the new compounds toward 
COX-2, pyrrole derivatives were submitted to molecular docking 
simulations and structural optimization of the resulting ligand-
COX-2 complexes. However, the software Autodock, chosen 
among docking programs available, was checked for its ability to 
find reliable poses (orientations) and conformations of ligands into 
the COX-2 binding site. For this purpose, the crystal structure of the 
enzyme co-crystallized with SC558 (7), an inhibitor of the coxib 
family, was used to set the optimal parameters of Autodock runs 
and to verify that such parameters could be applied to handle flexi-
ble diaryl five-membered inhibitors. In particular, the COX-2 
atomic coordinates used in the modeling studies were taken from 
the Protein Data Bank entry 6cox. Residues belonging to chain B 
and three N-acetyl-D-glucosamine residues present in chain A of the 
crystal structure were removed and excluded from all the calcula-
tions. The structure of the inhibitor was extracted from the complex 
with COX-2 and then re-docked into the enzyme binding site by 
means of Autodock. As a result, a very good agreement between the 
calculated (from docking simulations) and experimental (from the 
crystallographic complex) coordinates of SC558 (7) was found, the 
root mean square deviation (calculated on the heavy atoms) be-
tween the best ranking docked and minimized conformation of 
SC558 (7) and the corresponding crystallographic pose being of 
0.27 Å. Considering that the computational protocol was able to 
identify conformers of the inhibitor very similar to that found in the 
X-ray structure, this approach could be considered as a useful mod-
eling procedure to be applied for finding the orientations and inter-
actions of ligands inside the binding site of COX-2. The same set of 
Autodock parameters used during the preliminary calculations on 
SC558 (7) was also applied to the new pyrrole derivatives. How-
ever, considering that Autodock does not perform any structural 
optimization of the complexes obtained, a molecular mechan-
ics/energy minimization approach was also applied to refine dock-
ing output structures. All the amino acid residues at a 5 ? distance 
from ligand atoms were subjected to minimization, while the re-
maining amino acids were kept fixed. 
Table 8. Assessment of IC50 Values (i.e.the Concentration of the Drug Required to Inhibit COX Activity by 50%) for Platelet COX-1 and Mono-
cyte COX-2 Activities for Celecoxib, Valdecoxib, and a Selection of the Most Active Compounds by Using the Human whole Blood As-
says [13a, b] In Vitro. Selectivity Index is COX-1/COX-2 IC50 Ratio 
 
IC50 ( μM)  
Compd 
 COX-1 COX-2 
Selectivity Index 
(SI) 
19 132 7 19 
23 125 17 7 
30 20.4 2.1 9.7 
(+/-)-45a 21.3 3.8 5.6 
56 86 1.3 66 
59 20 2.5 8 
61 24 2 12 
Celecoxib 12.5 0.54 23 
Valdecoxib 34.3 0.66 52 
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Molecular docking simulations and structural optimization of 
the docked complexes showed the vicinal diaryl system and the 
central heterocyclic nucleus of both SC558 (7) and the new pyrrole 
derivatives located within the same regions of the COX-2 binding 
site. In general, the N1 aryl moiety of pyrroles and the bromophenyl 
group of the co-crystallized inhibitor share a region of the binding 
site thereafter referred to as the hydrophobic pocket (following the 
notation applied by Kurumbail and co-workers) comprising the side 
chains of lipophilic (Lue384) and aromatic (Tyr385, Trp387, and 
Phe518) amino acids (Fig. 2) [42]; the sulphur-containing groups 
were located within the selectivity site; the trifluoromethyl group of 
SC558 (7) and the side chain at C3 of pyrrole derivatives occupied 
the classical NSAID’s carboxylate binding site. Several hydropho-
bic contacts (between the N1 substituent and the hydrophobic 
pocket, between the C5 phenyl ring and Leu352 and Val523 of the 
selectivity site, between the terminal alkyl group of the C3 side 
chain and Val116 and Tyr355 of the carboxylate site, between the 
C2 methyl substituent and the side chains of Val349 and Ala527) 
and a network of hydrogen bonds (between the sulfone oxygens and 
both Phe518 NH and Gln192 NH2, between the ester/ether oxygens 
and the Arg120 guanidino group) stabilized the complexes between 
COX-2 and pyrrole derivatives. 
To further support the results of molecular docking simulations, 
the software Grid was also applied to evaluate the regions of best 
interactions between inhibitors and macromolecule. Grid probes 
able to mimic the physicochemical properties of the atom types and 
the substituents commonly found in ligands were used to calculate 
the interaction energy with amino acids constituting the COX-2 
binding site. The carbonyl Grid map (generated with the O probe) 
was in agreement with the docking results, showing that the Arg120 
side chain is surrounded by regions of profitable interactions with a 
carbonyl group, also including the position occupied by the car-
bonyl ester and ether groups of pyrrole derivatives. Moreover, it is 
important to note that, although additional space was available for 
alkyl groups longer than an ethyl substituent in the region where the 
ester alkyl chain was accommodated, the C3 grid (generated with 
the methyl probe) seemed to suggest that a two-carbon atom group 
was the optimal substituent to be used as the terminal portion of the 
ester chain. In fact, a region of profitable interactions between a 
methyl group and the protein was found in correspondence of the 
terminal methyl group of the ethyl ester chain of pyrrole inhibitors. 
Finally, inspection of the grid generated with the methyl probe 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Left panel. Graphical representation of the COX-2 binding site accommodating the inhibitor SC-558 (represented as van der Waals surfaces) in its 
crystallographic pose (entry 6cox of the protein data bank). Arg513 and His90 are able to form hydrogen bond contacts with the sulfonamide moiety of the 
inhihitor, differently to that found in the complex between celecoxib and COX-1. Right panel. Graphical representation of the COX-1 binding site accommo-
dating celecoxib (represented as van der Waals surfaces) in its crystallographic pose (entry 3kk6 of the protein data bank). Distance between His513 and the 
sulfonamido moiety of celecoxib is higher than that found between Arg513 of COX-2 and SC-558. As a consequence, His513 does not make any hydrogen 
bond contacts with the sulfonamide moiety of the inhihitor, differently to that found in the complex between SC-558 and COX-2. A different spatial location 
of Ile434-Phe518 was found in comparison to that of Val434-Phe518 of COX-2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Binding pose of SC-558 (ball and stick) and 28 into the COX-2 
binding site. The halophenyl moieties lie into the hydrophobic pocket (re-
gion A), the sulphonyl groups are located into the selectivity site (B), and 
the trifluoromethyl group of SC-558 is superposed to the ester side chain of 
6 within the carboxylate site (region C). 
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showed positive interactions between the 2-methyl group and the 
pocket defined by the side chains of Val349 and Ala527, in agree-
ment with docking results and with previous findings suggesting 
that such a substituent at this position yields the optimal potency 
[32]. Analysis of the C3 grid showed additional stabilizing interac-
tions involving the two para substituents of the 1,5-diaryl system of 
the inhibitor. This result was in agreement with the presence of a 
methyl group at the para position of the 5-phenyl ring of several 
COX-2 inhibitors, such as celecoxib. The Grid map generated for a 
trifluoromethyl group also gave interesting results. In detail, the 
best interaction with COX-2 was found in the region where the 
trifluoromethyl group of SC-558 (7) was located in the crystallo-
graphic structure. Changing the CF3 probe into a fluorine probe, 
three major interaction sites were found. However, one of them was 
worthy of further consideration, suggesting that a fluorine substitu-
ent at the para positions of the 1-phenyl ring (similarly to the bro-
mine of SC558) and, additionally, at the meta position of the same 
ring could improve the interaction with COX-2, involving Trp387, 
Tyr348, and Tyr385 of the hydrophobic cavity. On the basis of such 
considerations, molecular modeling simulations suggested struc-
tural modifications of the parent compounds aimed at synthesizing 
a second generation of pyrrole derivatives endowed with an im-
proved biological profile. In agreement, fluorinated derivatives 
were found to have a very low IC50 toward COX-2 (up to a 10 nM 
concentration) with a selectivity index [expressed as the ratio be-
tween IC50(COX-1)/IC50(COX-2)] higher than 10000, further vali-
dating the reliability of the computational protocol in finding the 
binding mode of 1,5-diaryl-2-methyl-3-substituted pyrrole deriva-
tives within the COX-2 binding site. 
Moreover, molecular docking simulations were also able to ac-
count for the marked decrease of activity toward COX-2 (up to 270-
fold) due to the inversion of the substitution pattern at positions 1 
and 5 of the pyrrole ring. In fact, a reorientation of the inhibitors 
within the binding site led to a different and less profitable interac-
tion pattern with the enzyme. The p-methylsulfonylphenyl moiety 
at N1 was accommodated within the carboxylate site and the ester 
side chain at C3 matched the selectivity site, while the remaining 
aryl moiety at C5 filled the hydrophobic pocket, as found for the N1 
aryl substituent of the corresponding isomer. Although these poses 
showed electrostatic and hydrophobic interactions that contributed 
to the stabilization of the complex with COX-2, they lacked addi-
tional contacts found in the corresponding isomers, such as hydro-
gen bonds at both the carboxylate and the selectivity site (with 
Arg120 and Gln192, respectively), as well as hydrophobic interac-
tions involving the methyl group at the pyrrole C2. 
Previous results of modeling calculations, as well as biological 
data and SAR considerations were taken into account for further 
optimizing pyrrole compounds into better hits. In particular, the 
nature and the mutual position of the substituents at both the phenyl 
rings at C5 and N1 positions was found to influence affinity toward 
COX-2: the marked difference in activity among the ester deriva-
tives suggested the importance of the SO2Me pharmacophoric por-
tion in the phenyl ring when placed at C5 instead of N1, and SAR 
data indicate that the SO2Me at the C5 phenyl ring and a fluorine 
substituent at the N1 phenyl ring are cooperative determinants of 
both potent and selective COX-2 inhibition (Table 1). Moreover, 
inspection of the binding mode of pyrrole derivatives bearing an 
acetic acid ethyl ester moiety at C3 led to the suggestion that its 
terminal alkyl moiety was very important for hydrophobic interac-
tions with Val116 and Tyr355, and substituents larger than an ethyl 
group could be accommodated within the carboxylate site. Accord-
ingly, the methylsulfonyl group was kept fixed at the para position 
of the C5 phenyl ring, several small substituents were used to deco-
rate the N1 phenyl ring, while the size and length of the ester chain 
at C3 were modified by insertion of different alkyl groups. In par-
ticular, butyl and isopropyl groups were chosen as the terminal 
portion of the ester moiety with the aim of satisfying the geometri-
cal constraint suggested by Grid calculations with the methyl probe. 
Docking simulations on pyrrole derivatives bearing bulkier ester 
functions showed that the isopropyl moiety, having the same length 
of an ethyl group and a larger size, occupied the Grid minimum 
point of the C3 probe. On the other hand, the butyl chain assumed a 
folded conformation with its carbon atoms accommodated in a re-
gion corresponding to the Grid C3 best interaction point, and thus 
making similar hydrophobic contacts with enzyme residues. As 
expected, such compounds showed a very impressive inhibition of 
COX-2 (the best value being 0.007 μM) and a selectivity index 
higher than 2300 (Table 4), resulting in a significant improvement 
with respect to parent compounds. 
Transforming the ester side chain at position 3 of the pyrrole 
nucleus into the corresponding acidic group (Table 1) did not sig-
nificantly influence orientation of compounds within the COX-2 
binding site. Acidic compounds were docked in both their proto-
nated and unprotonated forms, but no substantial difference was 
found in their binding mode. In principal, the best orientations of 
both forms of acidic compounds filled the binding site of COX-2 
similarly to the corresponding ester derivatives. Moreover, both 
forms of the optimized complexes were able to form a network of 
three hydrogen bonds with the guanidino group of Arg120 (car-
boxylate site), while one of the sulfone oxygens interacted by a 
hydrogen bond with the NH backbone group of Phe518 within the 
selectivity site (similarly to the ester derivatives). However, a trend 
in activity was found showing that esters were in general more ac-
tive than the corresponding acidic analogues, because of hydropho-
bic interactions involving the terminal alkyl chain of the ester func-
tion and residues of the carboxylate site (such as Leu93, Val116, 
Tyr355, and Leu359). 
On the contrary, the conformational rigidity introduced into 
keto-ester derivatives (Table 1) significantly influenced the binding 
mode of such compounds within the COX-2 binding site. In fact, 
the best orientation of these derivatives showed an interaction pat-
tern characterized by the methylsulfone group located within the 
hydrophobic pocket, while the C2 methyl group matched the car-
boxylate site. In such an orientation, although the ester carbonyl 
group of the inhibitor was able to make the usual hydrogen bond 
with the NH backbone group of Phe518 (selectivity site), additional 
interactions (i.e., the hydrogen bond between the ester chain and 
Arg120 and the hydrophobic interactions with the hydrophobic 
pocket) important for a profitable binding within the active site, 
were lost. On the basis of their lower affinity with respect to the 
corresponding ester and acidic derivatives (and consequent lower 
selectivity between the two forms of the enzyme), probably due to 
the different structural properties introduced into the side chain at 
the position 3 on the pyrrole nucleus, keto-esters were considered 
not much attractive compounds and were not investigated further. 
Transformation of the ester moiety into an ether substituent led 
to compounds that retained an unexpected very good affinity to-
ward COX-2 (Table 3). In fact, since the oxygen atoms of the ester 
chain were involved in a network of hydrogen bonds with Arg120 
of the carboxylate site, it was in principle difficult to understand 
why ether derivatives could have highly selective and potent COX-
2 inhibitory activity, even in the absence of the carbonyl group. An 
analysis of the interaction pattern with COX-2 binding site showed 
that the ether oxygen atom contacted the guanidino moiety of 
Arg120, while the alkyl portion of the ether chain was accommo-
dated within a hydrophobic region, defined by Leu93, Val116, and 
Leu359, where the best interaction point with a C3 probe was found 
by Grid. This means that the sole ether oxygen could serve as a 
profitable anchor point for the electrostatic interactions with the 
carboxylate site, reinforced by hydrophobic contacts between the 
more lipophilic alkoxyethyl moiety and the hydrophobic environ-
ment of the carboxylate site itself. 
Biological data showing that replacement of the ester function 
at the C3 position of the pyrrole nucleus with the corresponding 
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acidic and ether groups led to compounds with an important affinity 
toward COX-2, suggested that position 3 of pyrrole was permissive 
and tolerant to a number of substituents and functional groups, as 
already reported in the literature [42]. However, C3 substituents 
obtained by transformation of the methylenic bridge of ethyl esters 
into a chiral center bearing an alcohol or ether substituent, were not 
optimal for interacting with the COX-2 binding site. In fact, al-
though the new chiral derivatives adopted a binding mode very 
similar to that previously described for the corresponding achiral 
parent compounds and several groups of the ligands (such as the 
sulfonylmethyl and the carbonyl moieties) were confirmed as im-
portant anchor points for the binding of COX-2 inhibitors, their 
interactions with the amino acids of the COX-2 binding site were 
less profitable in comparison to those found for the corresponding 
ester, acid, and ether derivatives, thus accounting for their lower 
affinity toward COX-2. 
CONCLUSIONS 
Based on the results elicited from the compounds reported in 
this review, some considerations can be drawn:  
• the position of the p-methylsulfonyl moiety was very im-
portant for the activity (as reported before); 
• substituents and substitution pattern on the phenyl ring at 
N1 affected the activity, establishing a scale of activity; 
• the branched side chains at C3 of the pyrrole could better 
interact with the corresponding pocket of the enzyme allow-
ing an increased penetration into the pocket C, and, as a 
consequence, a shorter distance from the residue of Leu359, 
responsible for interaction. 
In general, the esters proved to be more active than the corre-
sponding acids and ketoesters. The discrepancy detected between 
the HWB and the cell culture assays could be due to the related 
different inhibitory sensitivity of the mouse and human COX 
isozymes. The compounds showed a very good activity against 
carrageenan-induced hyperalgesia, proving to be very effective and 
long lasting active, having been observed in this test a relevant 
analgesia still present at 2 hours after administration. In parallel, a 
very good activity was demonstrated in the carrageenan-induced 
oedema in the rat paw test and a dose-dependent anti-nociceptive 
activity in the abdominal constriction test.  
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ABBREVIATIONS 
t-NSAIDs = traditional Non-Steroidal Anti-inflammatory Drugs 
NSAIDs = Non-Steroidal Anti-inflammatory Drugs 
COX-2 = Cyclooxygenase-2  
COX-1 = Cyclooxygenase-1  
HWB = Human Whole Blood  
PG = Prostaglandin  
TX = Thromboxane  
AA = Arachidonic Acid 
IL-1? = interleukin-1?  
GI = Gastrointestinal  
RCTs = Randomized Clinical Trials  
UGIB = Upper Gastrointestinal Bleed  
MI = Myocardial Infarction  
LSS = Laminar Shear Stress  
TNF-? = Tumor Necrosis Factor-? 
DFU = 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-
methylsulphonyl)phenyl-2(5H)-furanone  
IP = PGI2 receptor 
SNPs = Single-nucleotide polymorphisms  
CV = Cardiovascular  
MAP = Mitogen-activated Protein  
ADME = Absorption, Distribution, Metabolism, Excretion 
SAR = Structure Activity Relationship 
HPLC = High Performance Liquid Chromatography 
SI = Selectivity Index  
REFERENCES 
[1] Burke, A.; Smyth, E.; FitzGerald, G.A. Analgesic-antipyretic agents: phar-
macotherapy of gout. In: Goodman & Gilman’s The Pharmacological Basis 
of Therapeutic; Brunton L.L., Lazo J.S., Parker K.L., editors. 11th edition. 
New York, NY: McGraw-Hill, 2006, 673-715. 
[2] Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. 
Science, 2001, 294, 1871-75. 
[3] Marnett, L.J.; Rowlinson, S.W.; Goodwin, D.C.; Kalgutkar, A.S.; Lanzo, 
C.A. Arachidonic acid oxygenation by COX-1 and COX-2: mechanisms of 
catalysis and inhibition. J. Biol. Chem., 1999, 274, 22903-06. 
[4] Kulmacz, J.; Wang, L.H. Comparison of hydroperoxide initiator require-
ments for the cyclooxygenase activities of prostaglandin H synthase-1 and -
2. J. Biol. Chem., 1995, 270, 24019-23. 
[5] Ueno, N.; Murakami, M.; Tanioka, T; Fujimori, K.; Tanabe, T.; Urade, Y.; 
Kudo, I. Coupling between cyclooxygenase, terminal prostanoid synthase, 
and phospholipase A2. J. Biol. Chem., 2001, 276, 34918-27. 
[6] FitzGerald, G.A. COX-2 and beyond: approaches to prostaglandin inhibition 
in human disease. Nat. Rev. Drug. Discov., 2003, 2, 879-90. 
[7] a)Xie, W.; Chipman, J.G.; Robertson, D.L.; Erikson, R.L.; Simmons, D.L. 
Expression of a mitogen-responsive gene encoding prostaglandin synthase is 
regulated by mRNA splicing. Proc. Natl. Acad. Sci. USA., 1991, 88, 2692-
96; b) Kujubu, D.A.; Herschman, H.R.; Dexamethasone inhibits mitogen in-
duction of the T1s10 prostaglandin synthase/cyclooxygenase gene. J. Biol. 
Chem., 1992, 267, 7991-94; c) O’Banion, M.K.;Winn, V.D.; Young, D.A. 
cDNA cloning and functional activity of a glucocorticoid-regulated 
inflammatory cyclooxygenase. Proc. Natl. Acad. Sci. USA., 1992, 89, 4888-
92. 
[8] Dixon, D.A.; Kaplan, C.D.; McIntyre, T.M.; Zimmerman, G.A.; Prescott, 
S.M. Post-transcriptional control of cyclooxygenase-2 gene expression: the 
role of the 3’-untranslated region. J. Biol. Chem., 2000, 275, 11750-57. 
[9] Simmons, L.; Botting, R.M.; Hla, T.Cyclooxygenase isozymes: the biology 
of prostaglandin synthesis and inhibition. Pharmacol. Rev., 2004, 56, 387-
437. 
[10] a)Rocca, B.; Spain, L.M.; Pure, E.; Langenbach, R.; Patrono, C.; FitzGerald, 
G.A. Distinct roles of prostaglandin H synthases 1 and 2 in T-cell develop-
ment. J. Clin. Invest., 1999, 103, 1469–77; b)Smith, W.L.; Langenbach, R. 
Why there are two cyclooxygenase isozymes. J. Clin. Invest., 2001, 107, 
1491–49; c) Yamagata, K.; Andreasson, K.I.; Kaufmann, W.E.; Barnes, 
C.A.; Worley, P.F. Expression of a mitogen-inducible cyclooxygenase in 
brain neurons: regulation by synaptic activityand glucocorticoids. Neuron, 
1993, 11, 371–86¸ d)Topper, J.N.; Cai, J.; Falb, D.; Gimbrone, M.A.Jr. Iden-
tification of vascular endothelial genes differentially responsive to fluid me-
chanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and 
endothelial cell nitric oxide synthase are selectively up-regulated by steady 
laminar shear stress. Proc. Natl. Acad. Sci. U.S.A., 1996, 93, 10417–22; 
e)Ferreri, N.R.; An, S.J.; McGiff, J.C. Cyclooxygenase-2 expression and 
function in the medullary thick ascending limb. Am. J. Physiol., 1999, 277, 
F360–F368¸ f)Harris, R.C.; Breyer, M.D. Physiological regulation of 
cyclooxygenase-2 in the kidney. Am. J. Physiol. Renal. Physiol., 2001, 281, 
F1–11. 
[11] Patrono, C.; Patrignani, P.; García Rodríguez, L.A. Cyclooxygenase-
selective inhibition of prostanoid formation: transducing biochemical selec-
tivity into clinical read-outs. J. Clin. Invest., 2001, 108(1),7-13. 
[12] a)Capone, M.L.; Tacconelli, S.; Di Francesco, L.; Sacchetti, A.; Sciulli, 
M.G.; Patrignani, P. Pharmacodynamic of cyclooxygenase inhibitors in hu-
mans. Prostaglandins Other Lipid Mediat., 2007, 82(1-4), 85-94; b)  
 
Enlarging the NSAIDs Family Current Medicinal Chemistry,  2011 Vol. 18, No. 10      1553 
Tacconelli, S.; Capone, M.L.; Patrignani, P.; Clinical pharmacology of novel 
selective COX-2 inhibitors. Curr. Pharm. Des., 2004, 10(6), 589-601.  
[13] a)Patrignani, P.; Panara, M.R.; Greco, A.; Fusco, O.; Natoli, C.; Iacobelli, S.; 
Cipollone, F.; Ganci, A.; Créminon, C.; Maclouf, J.; Patrono C. Biochemical 
and pharmacological characterization of the cyclooxygenase activity of hu-
man blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther., 
1994, 271, 1705-12; b) Patrono, C.; Ciabattoni, G.; Pinca, E.; Pugliese, F.; 
Castrucci, G.; De Salvo, A.; Satta, M.A.; Peskar, B.A. Low dose aspirin and 
inhibition of thromboxane B2 production in healthy subjects. Thromb. Res., 
1980, 17, 317-27. 
[14] a) Bombardier, C.; Laine, L.; Reicin, A.; Shapiro, D.; Burgos-Vargas, R.; 
Davis, B.; Day, R.; Ferraz, M.B.; Hawkey, C.J.; Hochberg, M.C.; Kvien, 
T.k.; Shnitzer, T.J. Comparison of upper gastrointestinal toxicity of rofecoxib 
and naproxen in atients with rheumatoid arthritis. VIGOR Study Group. N. 
Engl. J. Med., 2000, 343(21),1520-28; b) Schnitzer, T.J.; Burmester, G.R.; 
Mysler, E.; Hochberg, M.C.; Doherty, M.; Ehrsam, E.; Gitton, X.; Krammer, 
G.; Mellein, B.; Matchaba, P.; Gimona, A.; Hawkey, C.J. TARGET Study 
Group. Comparison of lumiracoxib with naproxen and ibuprofen in the 
Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), 
reduction in ulcer complications: randomised controlled trial. Lancet., 2004, 
364,665-74. 
[15] Kargman, S.; Charleson, S.; Cartwright, M.; Frank, J.; Riendeau, D.; Manc-
ini, J.; Evans, J.; O'Neill, G.C.; Characterization of prostaglandin G/H syn-
thase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastro-
enterology, 1996, 111,445–54. 
[16] a) Schmassmann, A.; Zoidl, G.; Peskar, B. M.; Waser, B.; Schmassmann-
Suhijar, D.; Gebbers, J.O.; Reubi, J. C. Role of the different isoforms of cy-
clooxygenase and nitric oxide synthase during gastric ulcer healing in cy-
clooxygenase-1 and -2 knockout mice. Am. J. Physiol. Gastrointest. Liver 
Physiol., 2006, 290(4), G747-56; b) Shigeta, J.; Takahashi, S.; Okabe, S. 
Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J. Pharma-
col. Exp. Ther., 1998, 286, 1383–90; c) Mizuno, H.; Akamatsu, T.; Kasuga, 
M. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibi-
tion by the specific antagonist delays healing in mice. Gastroenterology, 
1997, 112, 387–397; d) Jones, M.K.; Wang, H.; Peskar, B.M.; Levin, E.; 
Itani, R.M.; Sarfeh, I.J.; Tarnawski, A.S. Inhibition of angiogenesis by non-
steroidal anti-inflammatory drugs: insight into mechanism and implications 
for cancer growth and ulcer healing. Nat. Med., 1999, 5, 1418–23. 
[17] Masso González, E.L.; Patrignani, P.; Tacconelli, S.; Rodríguez, L.A. Vari-
ability of risk of upper gastrointestinal bleeding among nonsteroidal anti-
inflammatory drugs. Arthritis Rheum., 2010 in press.  
[18] Cryer, B.; Feldman, M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity 
of widely used nonsteroidal anti-infl ammatory drugs. Am. J. Med., 1998, 
104, 413–21. 
[19] García Rodríguez, L.A.; Tacconelli, S.; Patrignani P. Role of dose potency in 
the prediction of risk of myocardial infarction associated with nonsteroidal 
anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol., 
2008, 52(20), 1628-36. 
[20] Di Francesco, L.; Totani, L.; Dovizio, M.; Piccol, A.; Di Francesco, A.; 
Salvatore, T.; Pandolci, A.; Evangelista, V.; Dercho, R.A.; Seta, F.; Patrig-
nani P. Induction of prostacyclin by steady laminar shear stress suppresses 
tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human 
endothelial cells. Circ. Res., 2009, 104(4), 506-13. 
[21] Cheng, Y.; Wang, M.; Yu, Y.; Lawson, J.; Funk, C.D.; Fitzgerald, G.A. 
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascu-
lar function. J. Clin. Invest., 2006, 116, 1391-99. 
[22] Arehart, E.; Stitham, J.; Asselbergs, F.W.; Douville, K.; MacKenzie, T.; 
Fetalvero, K.M.; Gleim, S.; Kasza, Z.; Rao, Y.; Martel, L.; Segel, S.; Robb, 
J.; Kaplan, A.; Simons, M.; Powell, R.J.; Moore, J.H.; Rimm, E.B.; Martin, 
K.A.; Hwa, J. Acceleration of cardiovascular disease by a dysfunctional 
prostacyclin receptor mutation: potential implications for cyclooxygenase-2 
inhibition. Circ. Res., 2008, 102, 986-93. 
[23] a) Grosser, T.; Fries, S.; FitzGerald, G.A. Biological basis for the cardiovas-
cular consequences of COX-2 inhibition: therapeutic challenges and oppor-
tunities. J. Clin. Invest., 2006, 116, 4-15; b) Patrignani, P.; Capone, M.L.; 
Tacconelli, S. NSAIDs and cardiovascular disease. Heart, 2008, 94, 395-97. 
[24] Fries, S.; Grosser, T.; Price, T.S.; Lawson, J.; Kapoor, S.; DeMarco, S.; 
Pletcher, M.; Wiltshire, T.; FitzGerald G. Marked interindividual variability 
in the response to selective inhibitors of cyclooxygenase-2. Gastroenterol-
ogy, 2006, 130, 55-64. 
 [25] a) Biava, M.; Porretta, G.C.; Cappelli, A.; Vomero, S.; Botta, M.; Manetti, 
F.; Giorni, G.; Sautebin, L.; Rossi, A.; Makovec, F.; Anzini, M. 1,5-
Diarylpyrrole-3-acetic acids and esters as novel classes of potent and selec-
tive COX-2 inhibitors. J. Med. Chem., 2005, 48, 3428-32; b)Biava, M.; Por-
retta, G.C.; Poce, G.; Supino, S.; Forli, S.; Rovini, M.; Cappelli, A.; Manetti, 
F.; Botta, M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Vivoli, E.; 
Makovec, F.; Anzellotti, P.; Patrignani, P.; Anzini, M. COX-2 inhibitors. 1,5-
Diarylpyrrole-3-acetic esters with enhanced inhibitory activity toward COX-
2 and improved COX-2/COX-1 selectivity. J. Med. Chem., 2007, 50, 5403-
11; c) Biava, M.; Porretta, G.C.; Poce, G.; Supino, S.; Manetti, F.; Botta, M.; 
Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Makovec, 
F.; Anzellotti, P.; Cirilli, R.; Ferretti, R.; Gallinella, B.; La Torre, F.; Anzini, 
M.; Patrignani, P. Chiral alcohol and ether derivatives of the 1,5-
diarylpyrrole scaffold as novel antiinflammatory and analgesic agents. Syn- 
thesis, in vitro and in vivo biological evaluation and molecular docking simu- 
lations. Bioorg. Med. Chem., 2008, 16 (17), 8072-81; d) Biava, M.; Cirilli, 
R.; Fares, V.; Ferretti, R.; Gallinella, B.; La Torre, F.; Poce, G.; Porretta, G. 
C.; Supino, S.; Villani, C. HPLC enantioseparation and absolute configura- 
tion of novel anti-inflammatory pyrrole derivatives. Chirality, 2008, 20, 775-
80; e) Anzini, M.; Rovini, M.; Cappelli, A.; Vomero, S.; Manetti, F.; Botta, 
M.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelardini, C.; Norcini, M.; Giorda- 
ni, A.; Makovec, F.; Anzellotti, P.; Patrignani, P.; Biava, M. Synthesis, bio- 
logical evaluation, and enzyme docking simulations of 1,5-diarylpyrrole-3-
alkoxyethyl ethers as selective cyclooxygenase-2 inhibitors endowed with 
anti-inflammatory and antinociceptive activity. J. Med. Chem., 2008, 51, 
4476-81; f) Cappelli, A.; Anzini, M.; Biava, M.; Makovec, F.; Giordani, A.; 
Caselli, G.; Rovati, L. C. 3-Substituted-1,5-diaryl-2-alkyl-pyrroles highly se- 
lective and orally effective COX-2 inhibitors. PCT Int. Appl. 
WO2008014821 g) Biava, M.; Porretta, G.C.; Poce, G.; Battilocchio, C.; 
Manetti, F.; Botta, M.; Forli, S.; Sautebin, L.; Rossi, A.; Pergola, C.; Ghelar- 
dini, C.; Galeotti, N.; Makovec, F.; Giordani, A.; Anzellotti, P.; Patrignani P.; 
Anzini, M. Novel ester and acid derivatives of the 1,5-diarylpyrrole scaffold 
as anti-inflammatory and analgesic agents. Synthesis, in vitro and in vivo 
biological evaluation. J. Med. Chem., 2010, 53(2), 723-33.  
[26] Salter, E.A.; Wierzbicki, A.; Sperl, G.; Thompson, W. J. Molecular modeling 
study of COX-2 inhibition by diarylheterocycles and sulindac sulfide, J. 
MOl. Structure, 2001, 549, 111-121.  
[27] a) Jackson, P. F.; Bullington, J. L. Pyridinylimidazole based p38 MAP-
Kinase inhibitors. Curr. Top. Med. Chem., 2002, 2, 1011-20; b) Sawyer, J. 
S.; Beight D. W.; Britt K. S.; Anderson, B. D.; Campbell, R. M.; Goodson, 
Jr. T.; Herron, D. K.; Li, H.Y.; McMillen, W. T.; Mort, N.; Parsons, S.; 
Smith, E. C. R.; Wagner, J. R.; Faming Zhanga, L. Y.; Yingling, J. M. Syn-
thesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-
pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-b type I 
receptor kinase domain. Bioorg. Med. Chem. Lett., 2004, 14, 3581-84. 
[28] Liverton, N. J.; Butcher, J. W.; Claiborne, C. F.; Claremon, D. A.; Libby, B. 
E.; Nguyen, K. T.; Pitzenberger, S. M. Selnick, H. G.; Smith, G. R.; Tebben, 
A.; Vacca, J. P.; Varga, S. L.; Agarwal, L.; Dancheck, K.; Forsyth, A. J.; 
Fletcher, D. S.; Frantz, B.; Hanlon, W. A.; Harper, C. F.; Hofsess, S. J.; Kos-
tura, M.; Lin, J.; Luell, S.; O'Neill, E. A.; Orevillo, C.J.; Pang, M.; Parsons, 
J.; Rolando, A.; Sahly, Y.; Visco, D.M.; O'Keefe, S. J. Design and Synthesis 
of Potent, Selective, and Orally Bioavailable Tetrasubstituted Imidazole In-
hibitors of p38 Mitogen-Activated Protein Kinase. J. Med. Chem., 1999, 42, 
2180-2190.  
[29] McIntyre, C.J.; Ponticello, G.S.; Liverton, N.J.; O’Keefe, S.J.; Edward A. 
O’Neill, E.A.; Margaret Pang, M.; Schwartzb, C.D.; Claremona, D.A. Pyri-
dazine Based Inhibitors of p38 MAPK. Bioorg. Med. Chem. Lett., 2002, 12, 
689-692. 
[30] Seltzman, H.H. Recent CB1 Cannabinoid Receptor Antagonists and Inverse 
Agonists, Drug Development Research, 2009, 70, 601–615. 
[31] Rossi, R.; Bellina, F.; Synthesis and biological activity of pyrrole, pyrroline 
and pyrrolidine derivatives with two aryl groups on adjacent positions. Tet-
rahedron, 2006, 62, 7213-56. 
[32] Khanna, I. K.; Weier, R. M.; Paul, Y. Y.; Collins, W.; Miyashiro, J. M.; 
Koboldt, C. M.; Veenhuizen, A. W.; Currie, J. L.; Seibert, K.; Isakson, P. C. 
1,2-Diarylpyrroles as potent and selective inhibitors of cyclooxygenase-2. J. 
Med. Chem., 1997, 40, 1619-1633.  
[33] Ushiyama, S.; Yamada, T.; Murakami, Y.; Kumakura, S.; Inoue, S.; Suzuki, 
K.; Nakao, A.; Kawara, A.; Kimura, T. Preclinical pharmacology profile of 
CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinoci- 
ceptive and anti-inflammatory effects, Eur. J. Pharmacol., 2008, 578, 76-86. 
[34] Gierse, J.K.; Zhang, Y.; Hood, W.F.; et al., Valdecoxib: Assessment of 
cyclooxygenase-2 potency and selectivity J. Pharmacol. Exp. Ther., 2005, 
312, 1206-12. 
[35] Esser, R.; Berry, C.; Du, Z.; et al. Preclinical pharmacology of lumiracoxib: 
A novel selective inhibitor of cyclooxygenase-2. Br. J. Pharmacol., 2005, 
144, 538-50. 
[36] Khanapure, S.P.; Garvey, D.S.; Young, D.V.; et al. Synthesis and structure-
activity relationship of novel, highly potent metharyl and methcycloalkyl cy-
clooxygenase-2 (COX-2) selective inhibitors. J. Med. Chem., 2003, 4, 5484-
504. 
[37] Paramashivappa, R.; Kumar, P.P.; Rao, P.V.S.; Rao, A.S. Design, synthesis 
and biological evaluation of benzimidazole/benzothiazole and benzoxazole 
derivatives as cyclooxygenase inhibitors. Bioorg. Med. Chem. Lett., 2003, 
13, 657-60. 
[38] Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, 
D.; Falgueyret, J.-P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, I.; Mana-
cini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girad, Y.; Pra-
sit, P.; Zamboni, R.; Rodger, J. W.; Gresser, M.; Ford-Hutchinson, A. W.; 
Young, R. N.; Chan, C.-C. J. Pharmacol. Exp. Ther., 2001, 296, 558-566. 
1554    Current Medicinal Chemistry,  2011 Vol. 18, No. 10 Biava et al. 
[39] Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, 
J.R.. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-
oxygenase-2 are associated with human gastrointestinal toxicity: A full in vi-
tro analysis: Proc. Natl. Acad. Sci., 1999, 96, 7563-8. 
[40] Tegeder, I.; Lötsch, J.; Krebs, S.; Muth-Selbach, U.; Brune, K.; Geisslinger, 
G. Comparison of inhibitory effects of meloxicam and diclofenac on human 
thromboxane biosynthesis after single doses and at steady state. Clin. Phar-
macol. Ther., 1999, 65(5), 533-44. 
[41] Rimon, G.; Sidhu, R.S.; Lauver, D.A.; Lee, Y.J.; Sharma, N.P.; Yuan, C.; 
Frieler, R.A.; Trievel, R.C.; Lucchesi, B.R.; Smith, W.L. Coxibs interfere 
with the action of aspirin by binding tightly to one monomer of cyclooxy-
genase-1. Proc. Natl. Acad. Sci. USA, 2010, 107, 28-33. 
[42] Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, 
R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, 
K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition 
of Cyclooxygenase-2 by Anti-inflammatory Agents. Nature, 1996, 384, 644-
48. 
 
 
 
 
Received: December 15, 2010 Revised: March 07, 2011 Accepted: March 08, 2011 
 
